PL2803662T3 - Antagonista receptora p2x4 - Google Patents
Antagonista receptora p2x4Info
- Publication number
- PL2803662T3 PL2803662T3 PL13736295T PL13736295T PL2803662T3 PL 2803662 T3 PL2803662 T3 PL 2803662T3 PL 13736295 T PL13736295 T PL 13736295T PL 13736295 T PL13736295 T PL 13736295T PL 2803662 T3 PL2803662 T3 PL 2803662T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor antagonist
- antagonist
- receptor
- Prior art date
Links
- 102100037601 P2X purinoceptor 4 Human genes 0.000 title 1
- 101710189967 P2X purinoceptor 4 Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012005343 | 2012-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2803662T3 true PL2803662T3 (pl) | 2017-09-29 |
Family
ID=48781550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13736295T PL2803662T3 (pl) | 2012-01-13 | 2013-01-10 | Antagonista receptora p2x4 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9382236B2 (pl) |
| EP (1) | EP2803662B1 (pl) |
| JP (1) | JP6207399B2 (pl) |
| KR (2) | KR102092147B1 (pl) |
| CN (4) | CN111333588A (pl) |
| AU (1) | AU2013208536B2 (pl) |
| CA (1) | CA2861024C (pl) |
| DK (1) | DK2803662T3 (pl) |
| ES (1) | ES2626036T3 (pl) |
| IL (1) | IL233592B (pl) |
| NZ (1) | NZ627878A (pl) |
| PL (1) | PL2803662T3 (pl) |
| PT (1) | PT2803662T (pl) |
| SG (2) | SG11201404030YA (pl) |
| WO (1) | WO2013105608A1 (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627878A (en) | 2012-01-13 | 2016-03-31 | Nippon Chemiphar Co | P2x4 receptor antagonist |
| EP3020707B1 (en) * | 2013-07-12 | 2019-08-21 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| EP3020717B1 (en) | 2013-07-12 | 2021-12-15 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| WO2016151464A1 (en) | 2015-03-24 | 2016-09-29 | Piramal Enterprises Limited | An improved process for the preparation of clobazam and its intermediate |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| SG11201807543YA (en) | 2016-03-07 | 2018-09-27 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| JP7116679B2 (ja) * | 2016-04-28 | 2022-08-10 | 日本ケミファ株式会社 | 多発性硬化症の治療のための医薬 |
| SI3458443T1 (sl) | 2016-05-03 | 2020-11-30 | Bayer Pharma Aktiengesellschaft | Aromatski derivati sulfonamida |
| WO2018104305A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Field of application of the invention |
| WO2018104307A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4 |
| WO2018210729A1 (en) | 2017-05-18 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |
| AU2018326474B2 (en) | 2017-08-28 | 2024-07-25 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| AU2019233449B2 (en) * | 2018-03-14 | 2024-07-25 | Nippon Chemiphar Co., Ltd. | Medicament for treating cough |
| WO2020050253A1 (ja) * | 2018-09-03 | 2020-03-12 | 日本ケミファ株式会社 | 糖尿病性末梢神経障害のための医薬 |
| CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| CN113271946A (zh) | 2018-11-21 | 2021-08-17 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| KR20230041650A (ko) * | 2020-03-30 | 2023-03-24 | 유니베르시타＇ 디 피사 | 과민성 장 증후군 또는 염증성 장 질환의 예방 또는 치료를 위한 의약 |
| BR112022021391A2 (pt) * | 2020-06-30 | 2023-01-10 | Bayer Ag | N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 |
| CN115989218A (zh) * | 2020-06-30 | 2023-04-18 | 拜耳公司 | 具有p2x4受体拮抗活性的n-苯乙酰胺用于治疗某些眼部疾病的用途 |
| KR20230041005A (ko) * | 2020-08-03 | 2023-03-23 | 닛뽕 케미파 가부시키가이샤 | 알레르기 반응에 수반하는 증상의 예방 혹은 억제 또는 치료용의 의약 조성물 |
| WO2022049253A1 (en) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
| IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | Urea derivatives which can be used to treat cancer |
| EP4410310A4 (en) * | 2021-09-30 | 2025-10-22 | Nippon Chemiphar Co | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES |
| IT202100025124A1 (it) | 2021-09-30 | 2023-03-30 | Univ Degli Studi Di Firenze | Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale |
| JP2025041993A (ja) * | 2022-02-17 | 2025-03-27 | 国立大学法人鳥取大学 | 子宮内膜症又は子宮腺筋症の予防又は治療剤 |
| AU2023244778A1 (en) | 2022-03-31 | 2024-10-17 | Nippon Chemiphar Co., Ltd. | Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions |
| TW202448478A (zh) | 2023-02-24 | 2024-12-16 | 日商日本化美化股份有限公司 | 具有ｐ２ｘ４受體拮抗作用之化合物的固體分散體 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5534960Y2 (pl) | 1977-01-31 | 1980-08-18 | ||
| JPS53111093A (en) * | 1977-03-07 | 1978-09-28 | Takeda Chem Ind Ltd | Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation |
| JPH02304437A (ja) | 1989-05-19 | 1990-12-18 | Konica Corp | 新規な写真用カプラー |
| WO1995028419A1 (en) | 1994-04-14 | 1995-10-26 | Glaxo Wellcome Inc. | Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
| PE27497A1 (es) * | 1994-04-15 | 1997-08-07 | Glaxo Inc | Derivados de 1,5 benzodiazepina |
| SE0104250D0 (sv) * | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Heterocyclic compounds |
| WO2004041258A2 (fr) * | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
| DE10312969A1 (de) | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-on-Derivate |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| KR100512749B1 (ko) | 2004-01-14 | 2005-09-07 | 삼성전자주식회사 | 모니터장치 |
| US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
| WO2008023847A1 (en) | 2006-08-25 | 2008-02-28 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| SI2716301T1 (sl) | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| JP2012087053A (ja) | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | ジアゼピンジオン誘導体 |
| ES2432265T3 (es) * | 2009-02-16 | 2013-12-02 | Nippon Chemiphar Co., Ltd. | Derivado de diazepindiona |
| WO2012008478A1 (ja) * | 2010-07-13 | 2012-01-19 | 日本ケミファ株式会社 | Ｐ２ｘ４受容体拮抗剤 |
| JP2013209292A (ja) | 2010-07-23 | 2013-10-10 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| JP6325252B2 (ja) | 2011-05-25 | 2018-05-16 | 国立大学法人九州大学 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
| NZ627878A (en) | 2012-01-13 | 2016-03-31 | Nippon Chemiphar Co | P2x4 receptor antagonist |
-
2013
- 2013-01-10 NZ NZ627878A patent/NZ627878A/en unknown
- 2013-01-10 EP EP13736295.0A patent/EP2803662B1/en active Active
- 2013-01-10 JP JP2013553310A patent/JP6207399B2/ja active Active
- 2013-01-10 AU AU2013208536A patent/AU2013208536B2/en active Active
- 2013-01-10 CN CN202010213899.0A patent/CN111333588A/zh active Pending
- 2013-01-10 PT PT137362950T patent/PT2803662T/pt unknown
- 2013-01-10 DK DK13736295.0T patent/DK2803662T3/en active
- 2013-01-10 CN CN201380005473.4A patent/CN104066724B/zh active Active
- 2013-01-10 PL PL13736295T patent/PL2803662T3/pl unknown
- 2013-01-10 KR KR1020147022599A patent/KR102092147B1/ko active Active
- 2013-01-10 SG SG11201404030YA patent/SG11201404030YA/en unknown
- 2013-01-10 CA CA2861024A patent/CA2861024C/en active Active
- 2013-01-10 WO PCT/JP2013/050320 patent/WO2013105608A1/ja not_active Ceased
- 2013-01-10 ES ES13736295.0T patent/ES2626036T3/es active Active
- 2013-01-10 US US14/371,868 patent/US9382236B2/en active Active
- 2013-01-10 SG SG10201605325TA patent/SG10201605325TA/en unknown
- 2013-01-10 CN CN201910768337.XA patent/CN110483423A/zh active Pending
- 2013-01-10 KR KR1020207007764A patent/KR102140746B1/ko active Active
- 2013-01-10 CN CN201810753396.5A patent/CN108863959B/zh active Active
-
2014
- 2014-07-10 IL IL233592A patent/IL233592B/en active IP Right Grant
-
2016
- 2016-06-08 US US15/176,857 patent/US9969700B2/en active Active
-
2018
- 2018-03-16 US US15/923,685 patent/US10633349B2/en active Active
-
2020
- 2020-03-23 US US16/826,877 patent/US11434207B2/en active Active
-
2022
- 2022-07-22 US US17/871,201 patent/US12116351B2/en active Active
-
2024
- 2024-08-28 US US18/817,846 patent/US20240417379A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233592A0 (en) | p2x4 receptor antagonist | |
| GB201213700D0 (en) | Receptor antagnists II | |
| PT2927224T (pt) | Antagonistas de receptores | |
| IL238974B (en) | cxcr7 antagonists | |
| EP3020717A4 (en) | P2x4 receptor antagonist | |
| ZA201500781B (en) | 5-ht3 receptor antagonists | |
| HUE039607T2 (hu) | Progeszteron antagonisták | |
| ZA201305576B (en) | Trpm8 receptor antagonists | |
| IL232503A (en) | H2 - Indazoles as antagonists of the ep2 receptor | |
| EP2617717A4 (en) | ANTAGONIST OF P2X4 RECEIVER | |
| ZA201408172B (en) | V1a receptor agonists | |
| ZA201500220B (en) | Novel cholecystokinin receptor ligands | |
| GB201223053D0 (en) | Receptor | |
| GB2504611B (en) | Fastened Structure | |
| GB201213698D0 (en) | Receptor antagonists II | |
| GB201213699D0 (en) | Receptor antagonists II | |
| IL230334A0 (en) | Non-competitive nicotinic receptor antagonists | |
| PL2800497T3 (pl) | Unoszony oraz rozkładany mebel do siedzenia | |
| GB201210169D0 (en) | Seating |